scholarly journals Leukemic Blast Count

2020 ◽  
Author(s):  
Keyword(s):  
Leukemic Blast ◽  
Blast Count

Use of the mtt assay for rapid determination of chemosensitivity of human leukemic blast cells

1988 ◽  
Vol 12 (10) ◽  
pp. 823-831 ◽  
Author(s):  
Barbara G. Campling ◽  
John Pym ◽  
Peter R. Galbraith ◽  
Susan P.C. Cole
Keyword(s):  
Mtt Assay ◽  
Rapid Determination ◽  
Leukemic Blast ◽  
Blast Cells

scholarly journals Successful re-treatment with azacitidine in a patient with low blast count AML transformed from MDS after suspension of this agent

2015 ◽  
Vol 50 (2) ◽  
pp. 113 ◽  
Author(s):  
Pasquale Niscola ◽  
Andrea Tendas ◽  
Laura Scaramucci ◽  
Marco Giovannini ◽  
Stefano Fratoni ◽  
...  
Keyword(s):  
Blast Count

scholarly journals Pharmacogenomic markers of glucocorticoid response in the initial phase of remission induction therapy in childhood acute lymphoblastic leukemia

2018 ◽  
Vol 52 (3) ◽  
pp. 296-306 ◽  
Author(s):  
Vladimir Gasic ◽  
Branka Zukic ◽  
Biljana Stankovic ◽  
Dragana Janic ◽  
Lidija Dokmanovic ◽  
...  
Keyword(s):  
Retrospective Study ◽  
Acute Lymphoblastic Leukemia ◽  
Peripheral Blood ◽  
Initial Phase ◽  
Lymphoblastic Leukemia ◽  
Childhood Acute Lymphoblastic Leukemia ◽  
Remission Induction ◽  
Induction Treatment ◽  
Glucocorticoid Response ◽  
Blast Count

AbstractBackgroundResponse to glucocorticoid (GC) monotherapy in the initial phase of remission induction treatment in childhood acute lymphoblastic leukemia (ALL) represents important biomarker of prognosis and outcome. We aimed to study variants in several pharmacogenes (NR3C1,GSTsandABCB1) that could contribute to improvement of GC response through personalization of GC therapy.MethodsRetrospective study enrolling 122 ALL patients was carried out to analyze variants ofNR3C1(rs33389, rs33388 and rs6198),GSTT1(null genotype),GSTM1(null genotype),GSTP1(rs1695 and rs1138272) andABCB1(rs1128503, rs2032582 and rs1045642) genes using PCR-based methodology. The marker of GC response was blast count per microliter of peripheral blood on treatment day 8. We carried out analysis in which cut-off value for GC response was 1000 (according to Berlin-Frankfurt-Munster [BFM] protocol), as well as 100 or 0 blasts per microliter.ResultsCarriers of rareNR3C1rs6198 GG genotype were more likely to have blast count over 1000, than the non-carriers (p = 0.030).NR3C1CAA (rs33389-rs33388-rs6198) haplotype was associated with blast number below 1000 (p = 0.030).GSTP1GC haplotype carriers were more likely to have blast number below 1000 (p = 0.036), below 100 (p = 0.028) and to be blast negative (p = 0.054), whileGSTP1GT haplotype and rs1138272 T allele carriers were more likely to be blasts positive (p = 0.034 and p = 0.024, respectively).ABCB1CGT (rs1128503-rs2032582-rs1045642) haplotype carriers were more likely to be blast positive (p = 0.018).ConclusionsOur results have shown thatNR3C1rs6198 variant andGSTP1rs1695-rs1138272 haplotype are the most promising pharmacogenomic markers of GC response in ALL patients.

scholarly journals LEUKEMIC BLAST CELLS AND CONTROVERSIES IN MODELS OF HEMATOPOIESIS

2015 ◽  
Vol 37 (1) ◽  
pp. 2-4 ◽  
Author(s):  
D F Gluzman ◽  
L M Sklyarenko ◽  
M P Zavelevich ◽  
S V Koval ◽  
T S Ivanivskaya
Keyword(s):  
Acute Lymphoblastic Leukemia ◽  
Lymphoblastic Leukemia ◽  
Leukemic Blast ◽  
Acute Leukemias ◽  
Cell Lineages ◽  
Hematopoietic Lineage ◽  
Acute Monoblastic Leukemia ◽  
Blast Cells ◽  
The Common ◽  
Insight Into

Classical and up-to-date models of hematopoietic lineage determination are briefly reviewed with the focus on myeloid-based models challenging the existence of the common progenitor for T cells, B cells and NK cells. The analysis of immunophenotype of leukemic blast cells seems to be a promising approach for interpreting some controversies in the schemes of normal hematopoiesis. The liter ature data as well as our own findings in the patients with various types of acute leukemias are in favor of the concept postulating that common myeloid-lymphoid progenitors giving rise to T and B cell branches retain the myeloid potential. The similarity of some immunophenotypic features of blast cells in pro-B acute lymphoblastic leukemia and acute monoblastic leukemia is consistent with monocyte origin postulated in the studies of normal hematopoiesis. Study of acute leukemias may be the challenging area of research allowing for new insight into the origin of hematopoietic cell lineages.

scholarly journals Pathological Fracture: An Unusual Presentation in Childhood Chronic Myeloid Leukemia

2019 ◽  
Vol 13 (4) ◽  
pp. 140
Author(s):  
Mururul Aisyi ◽  
Ayu Hutami Syarif ◽  
Anita Meisita ◽  
Agus Kosasih ◽  
Achmad Basuki ◽  
...  
Keyword(s):  
Chronic Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Pathological Fracture ◽  
Hematological Malignancy ◽  
Blast Crisis ◽  
Philadelphia Chromosome ◽  
Molecular Response ◽  
Invasive Treatment ◽  
Non Invasive ◽  
Blast Count

Introduction: Chronic Myeloid Leukemia is a hematological malignancy driving from myeloproliferative process. It is typified by the presence of the Philadelphia chromosome manifesting in certain distinct complications, including pathological fracture. Pathological fracture is recognized as an extramedullary disease that occurs as a result of transformation of CML into blast crisis phase.Case Presentation: Here, we report a case of pediatric male CML. After being failed with imatinib therapy, he turned to nilotinib and was unable to achieve a major molecular response. He presented with high blast count and pain in the left arm. He was diagnosed with pathological fracture and blast crisis phase CML. Taken the young age and displacement of fracture into consideration, he was conservatively treated by a combination of immobilization and a higher dose of targeted therapy, nilotinib. The 2-month evaluation revealed clinical union and reduction of blast cells.Conclusions: Regarding the minimal displacement and age presentation, pathological fracture in pediatric CML requires non-invasive treatment and optimization of antileukemic therapy.

scholarly journals Leukemic Blast Clot Causing ST-Segment Elevation Myocardial Infarction

2018 ◽  
Vol 11 (16) ◽  
pp. 1656-1657 ◽  
Author(s):  
Emmanouil Skalidis ◽  
Ioannis Anastasiou ◽  
Ioannis Konstantinou ◽  
Stylianos Petousis ◽  
Eleni Papadaki ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Leukemic Blast ◽  
St Segment Elevation ◽  
Segment Elevation Myocardial Infarction ◽  
St Segment
Sign in / Sign up

Export Citation Format

Share Document